Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Kyle LaHucik

Biotech Correspondent

Eli Lilly is deepening its presence in the non-opioid pain field by buying California biotech SiteOne Therapeutics, which is in a similar arena as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

A new dawn for psychedelics? Compass could be the first to find out

Novo Nordisk ‘strongly’ urges against pharma tariffs as comments flood in

Weeks after TIGIT fail, iTeos decides to wind down

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B